Asunto(s)
Adenocarcinoma/complicaciones , Adenocarcinoma/genética , Síndrome Hipereosinofílico/complicaciones , Síndrome Hipereosinofílico/genética , Proteínas de Fusión Oncogénica/genética , Neoplasias Pancreáticas/complicaciones , Neoplasias Pancreáticas/genética , Anciano , Anciano de 80 o más Años , Cromosomas Humanos Par 12/genética , Cromosomas Humanos Par 15/genética , Enfermedad Crónica , Femenino , Humanos , Síndrome Hipereosinofílico/sangre , Hibridación Fluorescente in Situ , Translocación GenéticaRESUMEN
We report a case of multiple myeloma (MM) displaying an unusual course, with metastatic spread in uncommon sites (gastroduodenal and upper respiratory tract, breast, skin and liver) and with a fatal outcome. In our patient this plasma cell neoplasm was associated with a rare condition named crystal-storing histiocytosis (CSH), resulting from the storage in reactive histiocytes of crystalline immunoglobulin inclusions. These crystal-forming paraprotein components are secreted by the neoplastic plasma cells and give rise to the crystalline material of the histiocytes only after their ingestion and degradation by the same histiocytes. In this disorder crystal-storing cells may be present in various tissues (in our case mainly in bone marrow), often with functional alterations of the involved organs. In our opinion the association of this "atypical" MM with CSH is to be considered an uncommon event.
Asunto(s)
Enfermedades de la Médula Ósea/complicaciones , Histiocitosis/complicaciones , Inmunoglobulina A/análisis , Cadenas lambda de Inmunoglobulina/análisis , Mieloma Múltiple/complicaciones , Proteínas de Mieloma/análisis , Anciano , Biomarcadores de Tumor/análisis , Enfermedades de la Médula Ósea/patología , Cristalización , Resultado Fatal , Femenino , Histiocitos/química , Humanos , Mieloma Múltiple/química , Mieloma Múltiple/inmunología , Mieloma Múltiple/secundarioRESUMEN
PURPOSE: Although peripheral T-cell lymphoma, unspecified (PTCL/U), is the most common T-cell tumor in Western countries, no study to date has been based on the application of a wide panel of markers to a large series of patients and assessed the impact of phenotype on survival. We evaluated the expression of 19 markers in 148 PTCLs/U and 45 PTCLs of the angioimmunoblastic type (AILD). PATIENTS AND METHODS: The analysis was performed on tissue microarrays by immunohistochemistry and in situ hybridization. Clinical data were available in 93 PTCL/U patients, most of whom had been included in a previous study proposing a prognostic index (PIT). RESULTS: An aberrant phenotype with frequent loss of CD5 and/or CD7 was typical for PTCLs, irrespective of whether they were U or AILD. Aberrantly expressed proteins rarely included CD20, CD15, and CD30. Positivity for Epstein-Barr virus-associated small RNAs and CD15 expression emerged as adverse prognostic factors. Among PTCLs/U, the proliferation-associated protein Ki-67 turned out to be prognostically relevant and was integrated in a new predictive score, incorporating age (> 60 years), high lactate dehydrogenase, poor performance status, and Ki-67 > or = 80%. This score was associated with the patient outcome (P < .0001) and was found to be more robust than PIT (P = .0043) in the present series. CONCLUSION: Our retrospective analysis shows a wide range of protein expression in PTCLs and proposes a new prognostic index. The latter represents one of the first examples of mixed score (including patient- and tumor-specific factors) applied to malignant lymphomas and may be the basis for future prospective therapeutic trials.